Biogen terminates rights to SAGE 314 program.
Sage Therapeutics, Inc. announced that Biogen has terminated its rights under the collaboration and license agreement with Sage specific to the SAGE 324 program
The companies recently announced negative results from the Phase II KINETIC 2 Study of investigational SAGE 324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE 324 in ET. Sage and Biogen will continue to partner on Zurzuvae (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD. Under the terms of the collaboration and license agreement, the termination will be effective on February 17, 2025, and Sage will resume full ownership of the SAGE 324 asset at that time. Sage plans to continue to evaluate other potential indications, if any, for SAGE 324.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins